Screener
Organon OGN Nasonex — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Organon in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: Organon’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 8:46 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-029532
| ($ in millions) | Three Months Ended March 31, 2025 / U.S. | 2025 / Int’l | Total | U.S. | Int’l | Total |
|---|---|---|---|---|---|---|
| Other Cardiovascular (1) | 1 | 27 | 28 | — | 30 | 30 |
| Respiratory | ||||||
| Singulair | 2 | 38 | 40 | 2 | 72 | 74 |
| Nasonex | — | 65 | 65 | — | 71 | 72 |
| Dulera | 23 | 12 | 35 | 34 | 10 | 43 |
| Clarinex | 1 | 30 | 31 | — | 34 | 34 |
| Other Respiratory (1) | 11 | 1 | 12 | 10 | 3 | 13 |
| Non-Opioid Pain, Bone and Dermatology |
Item 1. Financial Statements (unaudited)
FAQ
- What is Organon's nasonex — revenue?
- Organon (OGN) reported nasonex — revenue of $65M in Q1 2026.
- How has Organon's nasonex — revenue changed year-over-year?
- Organon's nasonex — revenue decreased by 9.7% year-over-year, from $72M to $65M.
- What is the long-term trend for Organon's nasonex — revenue?
- Over 4 years (2021 to 2025), Organon's nasonex — revenue has grown at a 6.4% compound annual growth rate (CAGR), from $205M to $263M.
- What does nasonex — revenue mean?
- This metric represents the total gross revenue generated from the sale of the Nasonex product line within the established medicines portfolio. It reflects the market demand and commercial performance of this specific respiratory therapeutic asset. Monitoring these revenues helps investors assess the lifecycle maturity and revenue contribution of legacy pharmaceutical brands within the company's broader product mix.
Ask your AI about Organon's nasonex — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude